These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31805583)

  • 21. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.
    Chung KH; Kim W; Kim BG; Lee HY; Jin E; Cho Y; Seo JY; Kim HY; Jung YJ; Kim JW; Jeong JB; Lee KL
    Gut Liver; 2015 Sep; 9(5):657-64. PubMed ID: 25717049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is new on HBsAg and other diagnostic markers in HBV infection?
    Höner Zu Siederdissen C; Maasoumy B; Cornberg M
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):281-289. PubMed ID: 28774410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
    Baugh SDP
    Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rational selection of virologic and immunological biomarkers and therapeutic endpoints in the clinical trials of new drugs treating chronic hepatitis B].
    Cooperative Group of Basic Research and Experimental Diagnosis of Liver Diseases, Chinese Society of Hepatology, Chinese Medical Association
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):429-438. PubMed ID: 35545570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatitis B virus infection: control or cure?].
    Bourlière M; Oules V; Adhoute X
    Rev Prat; 2018 Mar; 68(3):276-282. PubMed ID: 30869285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B].
    Jia JD; Niu JQ; You H; Kong YY; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):97-101. PubMed ID: 33685074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
    Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
    Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers.
    Mak LY; Hui RW; Cheung KS; Fung J; Seto WK; Yuen MF
    Expert Opin Drug Discov; 2023 Apr; 18(4):401-416. PubMed ID: 36943183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The scientific basis of combination therapy for chronic hepatitis B functional cure.
    Lim SG; Baumert TF; Boni C; Gane E; Levrero M; Lok AS; Maini MK; Terrault NA; Zoulim F
    Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):238-253. PubMed ID: 36631717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
    Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
    Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
    Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
    Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.